Tianjin Biotech (IMAB, Financial) experienced a sharp decline in its stock price, falling by 5.07%. The shares are currently priced at $1.41, with a trading volume of 176,537 shares, a turnover rate of 0.23%, and a volatility of 7.43%.
Recent financial reports reveal that Tianjin Biotech recorded no operating income but posted a net loss of $17.82 million, translating to an earnings per share of -$0.30. The gross profit was also reported at $0.00, with a price-to-earnings ratio of -1.28.
According to institutional ratings, all three entities involved in rating this stock recommend a "buy," with none suggesting "hold" or "sell."
Within the biotechnology sector, where IMAB operates, there was an overall decline of 0.75%. In contrast, other stocks like Genprex, Inc., Biovie Inc., and Gri Bio, Inc. showed significant activity with high turnover rates and notable price swings.
Tianjin Biotech is a clinical-stage biotech company focused on developing transformative biologics for immuno-oncology and immuno-inflammation diseases, primarily in China and other regions. Its drug portfolio includes Uliledlimab (TJD5), an antibody targeting solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
